COL11A1 was overexpressed in bowel metastases among patients with ovarian cancer (38), and promoted ovarian cancer progression and is associated with chemo-resistance to cisplatin and paclitaxel in ovarian cancer cells (39). Here, COL11A1 is linked to ovarian carcinoma.